LifeLines
For the Southern California Life Science Community
9
Policy Wins For Biocom
13
Member Services: Responding to
Your Needs
18
STEM is the New Trend
The Forces Shaping Our Future
VOLUME 24, ISSUE 3 F a l l 2 0 1 5
ONE TEAM. ONE FOCUS.
www.sdlifesciences.com
LILLY
300,000 SF Tenant Representation
DEXCOM, INC.
218,000 SF Tenant Representation
TENANT REP
FOR THE
LIFE SCIENCES
INDUSTRY.
ALTHEADX
70,000 SF Tenant Representation
BRENT JACOBS
brent.jacobs@cushwake.com
CA License No. 791657
GREG BISCONTI
greg.bisconti@cushwake.com
CA License No. 1167920
TED JACOBS
ted.jacobs@cushwake.com
CA License No. 1855220
(858) 452-6500
ARCTURUS THERAPEUTICS
SYNTHETIC GENOMICS
BIOCOM
CUBIST
GENOMATICA
VERENIUM / BASF
10,000 SF Tenant Representation
45,000 SF Sublease Disposition
75,000 SF Tenant Representation
70,000 SF Tenant Representation
10,900 SF Tenant Representation
60,000 SF Tenant Representation
WELCOME
IN THIS ISSUE
2
By Joe Panetta,
President and CEO, Biocom
Cover Story: Five Undeniable Forces Shaping Our
Life Science Future
9 Public Policy : Policy Wins For Biocom
10Guest : An Intern’s Lens into the FDA
12Events: Biocom Launches New Speaker Series
13Membership: Member Services: Responding to
Your Needs
14Guest: Evaluating our Health Insurance Trust
17 Biocom Institute: Never Stop Learning
18 Science Festival: STEM is the New Trend
20Members in Action: Biocom Events
25Purchasing Group: Member Driven Evolution
26Premium Member Spotlights:
BioMed Realty, Bridge Bank, Dowling & Yahnke,
VWR, Biocom
30 Biocom Board and Committees
31 Biocom Membership
WELCOME TO LIFELINES
Welcome to the fall 2015 edition of LifeLines and our continuing 20th anniversary
celebration of Biocom, California’s longest established life science association.
With more than 700 members supporting the life science community, I am proud to
report that we are providing unsurpassed programs: robust advocacy at every level of
government; tremendous member services, including the Biocom Purchasing Group;
and outstanding partnering opportunities. In addition, through our relationships
with associations in Europe, Australia and Asia, we are raising capital for Southern
California.
As we have welcomed throngs of members to our new state-of-the art-facilities on
Torrey Pines Mesa, we appreciate the “Ecosystem of Innovation” that exemplifies this
region. I wish to personally thank all of our members – companies, research institutes,
the service sector and academia – who have so warmly welcomed us to the Torrey Pines
Mesa.
We have spent much of this anniversary year reflecting on the past: celebrating the
successes, large and small, that have helped grow the Southern California life science
industry into the powerhouse it is today. But in this LifeLines we are taking a decidedly
forward-looking approach, asking the question: What are the forces shaping our future?
We know from experience that it’s impossible to predict specifics. For example, if
E D I TO R : Jennifer Landress
CO P Y E D I TO R : Josh Baxt
DESIGN & LAYOUT: Arlene Arreola
you had asked me that question in 1995, I could never have forecast the immense
role genomics would play throughout the life science industry. The first human genome
sequence was still years from completion.
It’s also unlikely I could have foreseen the level of innovation this region would
produce in two short decades. Some of San Diego’s most groundbreaking therapeutics
VOLUME 24, ISSUE 3
such as Rituxan, Viracept and Byetta had not yet been commercialized. Influential San
Diego companies, such as Illumina, Nuvasive and Dexcom, had not even been founded
yet.
Still, while it is difficult to guess what the next 20 years will bring, we can (and
do) think hard about which factors will make us stronger and better-equipped to be
the global life science leader. Biocom is addressing these forces on many fronts:
from having a competitive talent pool to accessing capital. Through these measures,
our prowess will continue to expand in genetic sequencing, big data, manufacturing,
Biocom, a member driven
organization, is here to assist
life science companies like
yours to fulfill your most
ambitious goals. We can
help your company with
saving money, advocacy,
increased visibility, networking
opportunities, capital
development and workforce
development.
telemedicine and other areas. This industry is changing our world dramatically. We’ve
never been more excited to see what the future will bring.
Our advocacy initiatives continue to influence policy decisions on the local, state
and federal levels. Biocom’s board believes these efforts are best served through
regional association representation in partnership with our sister associations at the
regional and federal levels. In this issue, you will learn how we have been working hard
to create more opportunity for life science investment through the State of California,
and continuing our efforts to partner with legislative leaders, such as Congressman
Continued Pg 8
WWW.BIOCOM.ORG
Biocom LifeLines Fall 2015
1
COVER STORY
By Kelly Quigley, Canale Communications
Five Undeniable Forces Shaping Our Life
Science Future
From new venture funding strategies to the next generation of CEOs, here are some of the biggest factors shaping the
regional life science industry in years ahead.
As Biocom closes out its 20th year with a bang, many of us are
left pondering: What will Southern California’s life science industry
look like in another two decades?
What regional life science company will be capturing national
headlines with its breakthrough technology? What will be the next
blockbuster drug or life-changing medical device to emerge from
our ranks?
Interesting thoughts, to be sure. But given that innovation is
inherently unpredictable, is it even possible to foresee the twists
and turns that will shape the industry in the years leading to 2035?
If the past is any indication, the answer is probably no.
Since its modest beginnings in the late 1970s, the Southern
California life science industry has grown in unexpected and
remarkable ways—to the point where it’s now generating a hefty
$76 billion in economic activity each year.
Even in 1995, when Biocom was founded, it’s highly unlikely
that anyone could have predicted the explosive growth in genomics,
mobile health and synthetic biology, which have become critical
2
Biocom LifeLines Fall 2015
parts of the life science sector today.
But that’s not to say the industry’s success is surprising. Going
back to its earliest years, Biocom anticipated the key elements
that would be needed to create an environment ripe for innovation.
For example, a life science cluster of this size simply can’t thrive
without healthy government support, a rich academic infrastructure
and a diverse ecosystem of service providers. Biocom has devoted
much of its energy to ensuring that these and other essential
pieces are firmly in place.
As Biocom enters its third decade of growth, we take a look
at the factors shaping the sector’s evolution in the years ahead.
Although these innovations might not yet be apparent, the forces
that will lead to their creation are already here.
ONE
Money, money, money
Let’s face it. Innovation is expensive. Capital—and lots of it—
is needed to fund research, development and commercialization
COVER STORY
for groundbreaking life science products. If companies can’t get
money, they can’t change the world.
“As an industry, we’ve come to better understand molecular
biology and genomics, which produces even better healthcare
innovations,” says Carol Gallagher, Pharm.D., partner at venture
capital firm New Enterprise Associates. “But even as we gain
more knowledge, I don’t think the capital intensity is ever going to
decrease. That’s the challenge. To continue to create innovation,
we need capital from a variety of sources—a full ecosystem of
public investors, grant money and venture capital.”
So what’s the secret to keeping this ecosystem going? Is there a
magic business model that will grab investors’ attention in the years
ahead? Gallagher thinks not: “It always goes back to better therapies.
Sometimes
companies
get
overly
focused
on how cool the
science is and
forget about what
they’re doing for
the patient.”
Equally
as
important, life science companies must communicate how their
products fit into the existing healthcare system. If you have to
change how the system works, it’s going to be a harder sell.
Looking ahead, Gallagher wonders whether the relatively recent
“cross-over” investing craze will stick around for the long term.
Cross-over investing refers to would-be stock-market investors
funding a private company in advance of an expected initial public
offering. The model has provided added capital for promising
companies, giving them fuel to mature and expand. In the future,
will this model help create the next Amgen, Celgene or Genentech
right in our own backyard?
“Investors are, and will continue to be, willing to pay for
innovation that changes lives,” Gallagher says. “It’s important to
keep the engine of innovation strong; that’s what organizations like
Biocom are designed to do.”
“I DON’T THINK THE C APITAL
INTENSITY IS EVER GOING
TO DECREASE. THAT’S THE
CHALLENGE.”
TWO
Even bigger data
Say goodbye to gigabytes and terabytes, and roll out the welcome
mat for our new friend, the petabyte.
At a million gigabytes of data, the petabyte is what the industry
will increasingly need to store the reams of biological data produced
on today’s high-powered genomic sequencing machines.
For the folks at the San Diego Supercomputer Center at the
University of California, San Diego, the petabyte is nothing new.
They’ve been dealing with that magnitude of data for some time,
handling information-intensive computing for the national research
community, explains Wayne Pfeiffer, the center’s co-founder and
bioinformatics lead.
Among the center’s many ambitious projects is the Cancer
Cell Map Initiative, which seeks to determine how all cancer cell
components interact. The initiative will provide infrastructure for
the alliance between UC San Diego Health Sciences and San
Diego-based Human Longevity, which plans to generate thousands
of tumor genomes from UC San Diego cancer patients.
While the demand for such data-based healthcare applications
seems limitless today, things were much different when the center
started in 1985. “Our work was mainly in the physical sciences—
chemistry, physics, astronomy,” Pfeiffer says. “Biologists were
not dealing with data at this level. And certainly not healthcare
professionals.”
Today, genomic data is shaping nearly every facet of life
sciences, from the development of new diagnostics to personalized
medicines. “The larger and larger the databases become, the more
useful they are,” Pfeiffer says. With more data, it’s easier to spot
patterns and make connections between biomarkers and disease.
San Diego companies, including Illumina and Edico Genome,
are spearheading efforts to standardize the way genomic data is
recorded and shared to maximize clinical utility.
However, from a data perspective, storing every person’s
complete genomic profile isn’t realistic, Pfeiffer notes. Once fullgenome sequencing goes mainstream, it’s likely that only variants
will be stored—a tradeoff commonly made in other data-intensive
fields.
In the next 20 years, Pfeiffer predicts the genomic revolution
will have conquered many high-priority diseases and become
more
focused
on preventative
health. “Precision
medicine
isn’t
going to be just
for sick people,”
he says. “It’s
going to be helping healthy people live even longer, healthier lives.”
By then, perhaps the industry will already have moved on to the
zettabyte.
“PRECISION MEDICINE ISN’T
GOING TO BE JUST FOR SICK
PEOPLE.”
THREE
Consumer empowerment
Patients are increasingly knowledgeable about all things health
care—and their voices are rightfully carrying more weight than
ever. It’s a trend that’s expected to continue, leading to greater
transparency and more convenience across the healthcare
spectrum.
Continued Pg 5
Biocom LifeLines Fall 2015
3
[
]
Experience How Everything We Do
Has A Single Focus - Your Success
Focusing on private companies preparing to go public or be acquired,
we provide aaest and tax services to a wide variety of
public companies, early-stage and growing private companies.
We are one of San Diego’s largest
Life Sciences and Technology Praccces.
COVER STORY
This force is perhaps strongest in the fast-growing mobile
health sector, where patients are proactively tracking their body’s
metrics through health apps and accessing caregiver support from
anywhere that has a wireless connection.
Smartphones “are the most rapidly adopted technology in the
history of man,” writes Eric Topol, M.D., director of the Scripps
Translational Science Institute in San Diego, in his newest book
The Patient Will See You Now.
“If we liken the new model to the business world, the patient
becomes chief operating officer—a notable promotion from
nobody to senior
management,”
Topol observes.
Meanwhile,
government
healthcare
reforms
have
shifted towards
outcomes-based
reimbursement
models, demanding an additional level of reporting on the patient
experience.
“When you start thinking about healthcare in a consumer-centric
way, terms like empathy, delight, convenience and affordability
take on a greater significance,” says Nina Kjellson, general partner
at venture capital firm Canaan Partners, which is active in Southern
California healthcare IT. “Even life science companies need to be
thinking about this because increasingly, innovative products will
be judged not only on safety and efficacy but also on consumer
engagement.”
“WHEN YOU START THINKING
IN A CONSUMER-CENTRIC WAY,
TERMS LIKE EMPATHY, DELIGHT,
CONVENIENCE, AFFORDABILITY
TAKE
ON
A
GREATER
SIGNIFIC ANCE.”
FOUR
Sustainability
By 2035, the world population will have grown to more than
8 billion and life expectancy will be even longer than it is today.
More people will require our planet’s limited resources for a longer
amount of time. More water, more energy, more food, more goods.
Sustainability begins with an understanding that everything we
need for our wellbeing depends, either directly or indirectly, on
our natural environment. It’s the driving principle behind Southern
California’s booming biorenewables sector, which features an array
of companies focused on biofuels, specialty enzymes, renewable
chemicals and algae research.
“When you think about the challenges we currently face in the
world, be it food production or our use of energy, sustainability is
a topic that comes up again and again,” says Oliver Fetzer, CEO of
San Diego-based Synthetic Genomics.
Co-founded by J. Craig Venter, Synthetic Genomics is dedicated
to genomics-driven solutions to address such global challenges.
Among its many projects is a research agreement with ExxonMobil
to develop highly
efficient
algae
strains
that
convert sunlight
and
carbon
dioxide into biofuel.
“The fact remains that we, as a planet, are burning more fossil
fuels every year and emitting more carbon dioxide,” Fetzer says.
“The link to global warming is no longer debatable.”
Just as unmet medical needs drive biopharmaceutical innovation,
global sustainability challenges will continue to create a thriving
market for synthetic biology and biorenewables, Fetzer notes.
“THE LINK TO GLOBAL WARMING
IS NO LONGER DEBATABLE.”
FIVE
Generation Z
Forbes calls them rebels with a cause. Entrepreneur says they’re
realists with an entrepreneurial edge. But it’s all speculation at
this point, as the youngest members of Generation Z are still in
elementary school.
One thing is certain: In 20 years, Generation Z will have made
its presence known in Southern California life science. They
will be the next crop of scientists, marketers, CEOs and venture
capitalists. And the most successful companies will be doing all the
right things to attract and retain the best of this new generation—
rethinking company culture and providing an environment in which
they’ll want to stay and prosper.
Along with compensation and leadership opportunities, companies
will need to create a physical space that speaks to new generations,
notes Tracy Murphy, regional vice president of BioMed Realty Trust
in San Diego. The workspace must evolve to meet a growing desire to
blend hard work
with
inspiring
diversion.
“Access
to
restaurants and
shopping in a
more
campuslike environment
will become the
standard design,
rather than the innovative exception,” Murphy says. “Companies
like Google have put a spotlight on the workspace and how it can
be open and enjoyable, where employees can work and collaborate
while also enjoying leisurely activities.”
Adding to the sustainability trend, the new generation of life
science leaders will seek out buildings with minimal carbon
“ACCESS TO RESTAURANTS AND
SHOPPING IN A MORE C AMPUSLIKE
ENVIRONMENT
WILL
BECOME THE STANDARD DESIGN,
RATHER THAN THE INNOVATIVE
EXCEPTION.”
Continued Pg 6
Biocom LifeLines Fall 2015
5
COVER STORY
footprints, she adds. They’ll demand green roofs, recycled water
for cooling and irrigation and fuel-cell technology for affordable
power. “We’re excited to see what the next 20 years will bring
because we know that the best has yet to come,” Murphy says.
That’s Not All…
There’s a range of other forces that will play a leading role in
the growth and evolution of the Southern California life science
industry:
Water. Yes, it’s possible to get even smarter about water usage,
and we will.
Stem cells. Regenerative medicine is growing fast, with dozens of
promising therapies at various stages of development. Cures are
more than a pipe dream.
Teamwork. Expect a greater level of collaboration among the life
science powerhouses in San Diego, Orange County and Los Angeles
as the SoCal region competes with other U.S. and international life
science clusters.
Make Your Mark
Policy. From taxes to NIH funding, Biocom is constantly tracking
legislation at the local, state and national levels, advocating for
policies that accelerate life science innovation.
Kelly Quigley is content director for Canale Communications and
a former biotech journalist. At CanaleComm, she specializes in
thought leadership strategy and content development for life science
companies.
in
BiotechnologY
Professional Science Master’s
The Professional Science Master’s in Biotechnology from CSUSM is a
degree that leads to jobs with graduates reporting a 97% employment
rate at time of graduation. This innovative degree incorporates advanced
biotechnology coursework and laboratory training with MBA-level
business courses. The part-time evening program accommodates the
needs of working professionals. Our graduates are well-prepared for
successful careers and advancement in the life science industry.
For more information contact us at www.csusm.edu/el/psmlifelines
HURRY!
Fall 2016 Start
APPLY
TODAY
WELCOME CONTINUED
February 24-25, 2016
By Joe Panetta,
President and CEO, Biocom
The Lodge
at Torrey Pines
Scott Peters, to protect intellectual property and successfully oppose
THE PREMIER
PARTNERING EVENT
2016
Biocom’s 6th Annual Global Life Science Partnering
Conference is an exclusive global partnering
and networking forum that brings together senior
executives, bankers, venture capitalists, and
business development professionals from leading
pharmaceutical and biotech companies.
The conference will include panel discussions on
relevant topics with senior industry leaders, start-up
company presentations, one-on-one meetings, and
numerous networking opportunities.
negative Congressional legislation.
Biocom’s membership recruitment is at an all-time high, but
we are also focused on member retention. The power of retention
ensures that our members have a long-term investment in Biocom,
that we build a network of members working together as a region and
that we invest in delivering better value for all members. This year,
I will personally hold more than 50 meetings with member CEOs
specific to retention, and my team will hold countless more with
company representatives.
We are especially pleased that our partners at Alexandria Real
Estate have provided amazing meeting and presentation facilities. We
can now hold a number of our events, including quarterly breakfast
meetings, at our facility. As a result, we are launching a variety
of new events, including a CFO speaker series and Fireside Chat
program with regional CEOs. Our first chat was a remarkably candid
and engaging discussion with Illumina CEO Jay Flatley in our on-site
Illumina Auditorium. I look forward to more next quarter.
We continue to pursue strong workforce education and training
programs. In this issue, we review where are they now, which
highlights individuals whose life science careers have benefitted
from these programs. In addition, our San Diego Festival of Science
and Engineering staff discuss how STEM is the new trend in
education and how the Festival is leading this movement.
Finally, you will read how the Biocom Purchasing Group, which we
began not long after Biocom was founded, is making a push to ensure
that all of our contracts, with more than 40 vendors, are competitive
on a global scale. The Purchasing Group continues to be the gold
standard for the life science industry, and we are making every effort
to increase its value for our members.
Please enjoy this issue of LifeLines, come by and visit our beautiful
new facility and engage with us as we continue to accelerate life
science success in our region.
www.biocom.org
PUBLIC
POLICY
By Jimmy Jackson,
Senior Vice President of Public Policy, Biocom
Policy Wins For Biocom
Policy wise, the past few months have been some of the most
eventful in Biocom’s 20-year history. As California’s oldest and
most established life science association, we are proud to represent
the broad interests of our membership.
With the state legislature adjourned, it has been a successful
year for Biocom’s state policy efforts. Only one bill Biocom
opposed, which governs consumer products, was signed into law
by Governor Jerry Brown; however, several bills we supported were
approved, including a bill (SB 671) creating a structure by which
biosimilars can be substituted for their reference product. One of
the most important bills to come out of this year’s session was AB
437, which would have allowed small businesses (annual revenues
below $5 million) to receive state grants for a percentage of their
unused R&D credits. Biocom organized a letter from its member
companies to Governor Brown urging him to sign this legislation –
46 companies signed on to this correspondence. Unfortunately,
this legislation, as well as all other proposals containing a tax
credit, was vetoed by the Governor on October 10.
Meanwhile, Congress continues to move toward its own mid-term
adjournment. Patent reform bills (HR 9 and S 1137), which could
adversely affect the life science industry, had been advancing
in Congress despite industry efforts to amend them. However,
lobbying by Biocom’s Washington DC office, in cooperation with
BIO, PhRMA, various regional life science associations and venture
capital, patient advocacy and other groups, led to the bills being
withdrawn for the time being. Biocom member companies also
weighed in on this issue with Congressional offices, using a letter
from Biocom urging House members to oppose HR 9.
In July, we responded to a letter co-authored by Congresswoman
Susan Davis, which was about to be circulated. The letter asked her
colleagues to advocate for a lower standard of data exclusivity in
the negotiations for the Trans-Pacific Partnership (TPP) agreement
than the 12 years that is law in the US. Biocom and CLSA teamed
up immediately to generate a joint letter asking members of
Congress not to sign on to the Blumenauer-Davis-Himes letter.
Partly as a result of Biocom and CLSA’s rapid response, this letter
secured only eight additional co-authors (out of a possible 432).
Unfortunately, the announcement was made that TPP would only
guarantee eight years of data exclusivity for biologics and Biocom
has communicated our disappointment to the California delegation
on this decision. In addition, Biocom’s Washington office remains
active on repealing the medical device tax and giving input for the
Senate version of the House’s 21st Century Cures Initiative.
On the local level, Biocom has been actively involved with the
County of San Diego’s working group on sharps disposal. The group
continues to review background information, including existing
infrastructure and sharps regulations in other jurisdictions.
Biocom continues to ask the County to update its website with a
comprehensive list of current take-back sites, including designated
take-back sites in the county program and private locations that
only take sharps from customers. We will continue to engage with
this group.
Finally, the Public Policy Department held two major events.
The first was a facilities workshop at the SDG&E Energy
Innovation Center to discuss facilities management challenges,
especially for people whom facility management is a small part
of larger responsibilities. We also held our Biocom PAC Annual
Elected Officials Reception at the beautiful Celgene campus.
The reception attracted one of the more diverse collections of
elected officials we have had at this event: Congressmen Darrell
Issa and Scott Peters; State Senator Marty Block, Assemblymen
Rocky Chavez and Brian Jones; County Supervisors Dianne Jacob
and Dave Roberts; and, from the City of San Diego, Mayor Kevin
Faulconer and Councilmembers Chris Cate, Todd Gloria, and Mark
Kersey. Assemblywomen Lorena Gonzalez and Shirley Weber were
scheduled to attend, but a Senate Appropriations Committee
hearing in Sacramento ran into the evening, preventing them from
making their flights. Speaker Toni Atkins was called away because
of her work on the Special Legislative Session on Transportation
and Infrastructure. We thank signature sponsor Genentech and
host sponsor Celgene for making this event possible.
Jimmy Jackson is the Senior Vice President
of Public Policy for Biocom. He oversees
government affairs and public policy for the
organization.
Biocom LifeLines Fall 2015
9
GUEST
By Veronica Bradley,
Student, UCSD Bioengineering
An Intern’s Lens into the FDA
In Spring of 2015, Veronica Bradley, a UCSD Bioengineering
student, met Biocom CEO Joe Panetta at a Bioengineering Career Day
on campus and expressed an interest in FDA regulatory policy as a
career. Joe, a former EPA regulator himself, invited her to attend a
Biocom breakfast meeting where Dr. Jeff Shuren, Director of the FDA’s
Center for Devices and Radiologic Health (CDRH), was to speak via
skype. Veronica was allowed to ask the first question, so she told
Shuren of her interest. He related that he had started at FDA as an
intern and suggested she apply for their internship program. Veronica
was accepted into the ten week internship program, and our budding
bioengineer recently shared some of her thoughts on the experience.
The whole experience at the FDA was incredible. The working
environment there truly seemed great. I thoroughly enjoyed all of my
coworkers. They were all very smart and very enjoyable to interact
with. And it was so wonderful getting a whole ten weeks to experience
Washington D.C. I also ventured up to Boston one weekend and New
York City two weekends, so I really got a fulfilling experience.
In my internship I was assigned to the ophthalmic section of CDRH.
I loved getting to learn so much about medical devices, both from
reading documentation of the review process and from discussions
with the people in my division. I particularly enjoyed reading about
the mechanical testing performed, due to my engineering major. I
was able to see how so much of what I’ve learned is applied in the
testing of devices. It gave me a new perspective on how essential
these concepts are in getting a device to market.
I had a specific project I was responsible for (as well as other side
projects), and it was so interesting to me. It was a challenge, but I was
able to complete it and feel that I accomplished something over the
ten weeks. Under the supervision of an experienced reviewer, I worked
with a fellow intern in gathering historical information regarding the
pre-clinical testing requirements that have historically been requested
for the clearance of Lacrimal System Repair devices.
After reading through extensive documentation of reviews for all the
lacrimal repair devices, including stents and balloons, that have been
brought to market over the past thirty years, I was able to create a
recommendation for the crucial testing and standards to be written into
the new regulation and special controls for this device type. Writing a
new regulation and guidance is a complicated process that takes time,
but the research I did and the spreadsheet of information I compiled
will serve as an essential starting point in the process. It felt good to
10
Biocom LifeLines Fall 2015
be able to make a contribution and to have so much support from the
division I worked in. The employees in the Division of Ophthalmic
and ENT Devices (DOED) taught me so much in my time there. From
lessons about the review process to details about the science behind
specific devices, it was all fascinating and eye-opening.
I very much appreciate the opportunity I got this summer. I
discovered my own interest in regulatory work, and also realized my
preference toward the engineering testing in particular. Needless to
say, the internship was invaluable, and I would strongly encourage
those in my discipline to apply for the program as it gives you unique
insight from the perspective of those reviewing applications. It is not
something I would have learned in a classroom, and I am sure no
matter what path my career takes after graduation, the experience will
make me more valuable as an employee and team member.
Veronica Bradley is studying Bioengineering
at UCSD.
TM
ProSci
Custom Monoclonal Abs
Against Challenging Antigens
ProSci’s Hybridoma Development
+



Phase I:
• 5 BALB/c mice
Immunization • ELISA screening
• ≥ 6 weeks
Special mAb Development
 Cell Surface Proteins
 Idiotype
Phase II:
Fusion
• 1 mouse spleen
• ELISA screening
• 2 weeks
 Single Amino Acid Mutations
 Small Molecules
• 2 subcloning steps
• ELISA screening
• 4-6 weeks
Call and use BIOCOM153
code for 25% off!
Cus
First time customers.
 Monoclonal Antibody Pairs
 Post Translational Modifications
Phase III:
Subcloning
•
•
•
•
NEW
VHH tom
A
Deve ntibody
lopm
ent
In vitro & ascites services available
>95% hybridoma fusion success rate
3 ELISA positive final clones guaranteed
Flexible entry and exit points for services
Custom
Your Antibody Experts
• >12,000 custom antibody projects completed since 1998
• In-house labs & 150,000 ft2 of animal facilities on 27 acres
• USDA licensed & NIH/OLAW assured facilities
prosci-inc.com | info@prosci-inc.com | (858) 513 2638
© 2015 ProSci Incorporated. All rights reserved.
ProSci is an antibody focused company and a leading
provider of custom antibody services and catalog
antibodies worldwide.
EVENTS
By Ashleigh Berry,
Manager of Events
Biocom Launches New Speaker Series
Ever wonder how Biocom events are organized and executed?
Do you have ideas for new topics or dynamic speakers? Would it
be interesting to help plan the 60-plus events and conferences
Biocom offers each year?
Well, you can. Biocom is always exploring innovative ways to
build our member event roster. We are
consistently evaluating our events to
ensure these programs are meeting our
members’ needs. The feedback we receive
from attendees is extremely helpful;
however, it’s the support from our event
planning committees that really guide us.
Our committees help us determine how to
structure programs, develop content and
identify which events are essential for our
members.
Earlier this year, in partnership with our
CFO committee, Biocom launched a new
speaker series geared towards CEOs and high-level executives. This
new series will be held twice a year and will highlight a CEO from a
billion-dollar life science company, providing a unique opportunity
to hear how these companies became successful and maintained
their value in the ever-changing capital markets.
With a market cap over $30 billion, it seemed appropriate to kick
off the first series with one of our region’s luminaries: Jay Flatley,
CEO at Illumina. Flatley sat alongside Joe Panetta, Biocom’s
president and CEO, to discuss the genomic revolution and how it
will advance health and wellbeing. Flatley was appointed president
and CEO of Illumina in 1999 and has increased revenue from $1.3
million in 2000 to more than $1.8 billion in 2014. He oversaw
the company’s expansion into whole genome sequencing, with
the Solexa acquisition in 2006, and more recently into clinical
markets, such as oncology and reproductive health.
In July 2015, more than 200 attendees heard Flatley discuss
his thoughts on Illumina’s past, present and future. He shared his
views on competition with start-up companies, genome sequencing
and much more.
Not surprisingly, attendees were eager to hear Flatley discuss
Roche’s hostile takeover attempt. After a collapse in stock price
dropped Illumina to $24 per share in December 2011, Roche
decided to acquire the company. Roche knew Illumina had
unbeatable sequencing technology and, with the stock price so
low, would be an easy takeover target. They were mistaken.
“One really important factor was that we do a rigorous strategic
12
Biocom LifeLines Fall 2015
planning every year, and it finishes in January,” said Flatley. “So at
the time they became hostile, we had a perfectly fresh three-year
strategic plan that allowed us to create a very strong case to our
shareholders.”
Flatley explained that neither their board nor their shareholders
ever waivered. Illumina is now trading
around $200 a share.
Flatley went on to discuss genome
sequencing. He explained that the more
genomes we sequence, the more accurate
the data will become, ultimately providing
a greater ability to drive preventive care.
Flatley was one of the first to have his
genome sequenced, discovering he has
malignant hypothermia, which can cause
sudden death under anesthesia. He can
now prevent this from happening.
Flatley’s story is just one example of how
genome sequencing can change lives. Illumina has successfully
lowered the cost for full genome sequencing to roughly $1,000,
and the current cost for individual sequencing is around $2,900.
Flatley hopes that, in the future, this will be paid by insurance.
Flatley ended his dynamic discussion by stating, “I’m sort of a
start-up guy, at least I used to be, and now I am managing this big
company. I’m sort of learning as I go.”
A highlights video of the event is now available on Biocom’s
YouTube channel. To watch this video, and view a list of Biocom’s
upcoming events, please visit www.biocom.org.
If you are interested in participating in one of Biocom’s event
planning committees for 2016, opportunitites are available with
DeviceFest, the California Life Science HR Conference, Outsourced
Pharma West Conference and BIO 2016.
Ashleigh Berry is the Manager of Events for
Biocom and is in charge of organizing and
marketing Biocom Events.
MEMBERSHIP
By Michelle Wright,
Manager of Membership
Member Services: Responding to Your Needs
Biocom is always listening, and we pride ourselves on keeping
the lines of communication open. This means meeting with our
members, listening carefully to their needs and understanding each
company’s challenges and goals. These ongoing conversations help
us allocate our resources to ensure we provide the best possible
services.
One way we’ve responded to these conversations is to increase
our efforts to support employees and help them get involved with
their life science community. Each year, Biocom offers more
than 75 events to help staff grow their personal and professional
networks. In the same vein, we also have 15 committees, such as
CRO, legislative and medical devices to join, we host professional
development courses, offer speaking opportunities on a wide
variety of panels, offer volunteering opportunities at the San
Diego Festival of Science & Engineering Expo Day and produce
the Biocommunique eNewsletter to keep members abreast of the
latest life science news. In addition, our Employee Perks program
helps members save money at local businesses.
Naturally, we also offer many opportunities for companies to
sponsor events, as well as connecting member companies to keep
contracts and collaborations in the family. More than 93 percent
of companies who use the Biocom Purchasing Group recoup their
membership investment each year – many save 15 to 25 times
their annual dues. Given these perks, it’s no surprise that Biocom
has such high retention.
Most recent, one of the top requests members have is to forge
closer relationships with clinical sites. To help support this request,
we host a variety of events that focus on specific therapeutic areas.
Many more of these events are coming in 2016.
We also help companies get valuable face-time with key
dealmakers during Venture Days, Partner Days and Biocom’s
Global Life Science Partnering Conference.
telemedicine to genomic testing. These technologies allow
patients to communicate directly with their physicians, transmit
health care information instantly in a home setting, and
empower them to be active participants in their everyday care
management. Studies also show that they help reduce costs and
improve patient outcomes across a wide spectrum of disease
conditions. Our mission is to support digital health innovation
in our region thus making Southern California the epicenter of
wireless health.
Big Data
Biocom’s Big Data/Informatics initiative recognizes that
companies everywhere are trying to manage a big data tsunami.
From molecular diagnostics to patient data, our members are
faced with the unique challenge of separating nuggets of
important, actionable data from gigabytes of statistical noise.
This initiative helps identify the new trends and best practices
in data generation, knowledge management and information
technology.
If you would like to discuss ways to get more plugged into
your membership or review your benefits, please contact me at
858.455.0300 x116 or mwright@biocom.org.
Michelle is the Manager of Membership for
Biocom and oversees the Medical Device
Committee for the organization
NEW INITIATIVES
There are a number of major life science issues, but two of
the biggest are digital health and big data. To stay on the leading
edge of these and other trends, Biocom continues to develop
new initiatives to educate stakeholders and show off some of our
member’s most important advances.
Digital Health
Health care is at the cusp of a sector-wide transformation due
in large part to the development of digital health technologies,
from mobile applications to remote patient monitoring to
Biocom LifeLines Fall 2015
13
BENEFITS
Evaluating our Health Insurance Trust
The Beyond Benefits Trust, a health benefits program exclusively
increases heading into 2016. The industry average is in the
for Biocom members, gives California life science companies
high teens. This gap will continue to increase, pulling the trust’s
access to best-in-class group health insurance. The trust was
premiums further away from industry norms and making it the
created after a two-year competitive bidding process, which was
clear choice for companies with more than four employees.
organized by the Biocom Purchasing
Because of the trust’s performance,
Group and BayBio in 2012.
Anthem has also agreed to quote a
Come January 1, 2016 employers
Beyond Benefits won out over of a
5 to 7 percent discount on larger
with 51-100 employees will be categorized as
number of group health insurance
groups that may have credibility on
“SMALL GROUP EMPLOYERS”
candidates, including PEO’s, selftheir own or may be considering selfinsured models, other MEWA trusts
insuring. I’m sure you can imagine
The
What does
and several stand-alone discount
what 5 to 7 percent off a large group
this mean?
insurance programs.
health premium could mean to a
so good stuff...
The Beyond Benefits Trust, like
company’s bottom line. We have
Medical rates will now be based on each
The
covered family members’ age and zip code of
the employer.
all of our contracts, was selected
worked extensively with Anthem to
...
Depending on your company’s size, medical
by a committee of experts, from our
provide this benefit and appreciate
rates could increase 30-40%.
Enroll in a Department of Labor-qualified
small business trust, like...
member base and board of directors,
their investment in our industry and
Impact on Employers
who bring decades of industry
our member base.
Lose
Gain
Underwriting discounts
knowledge and expertise. We are
We cannot underscore enough how
Rising medical
for industry and
premiums
demographics
very fortunate to have a strong
important it is that these discounted
Keep your large group qualification, regardless
More administrative
Online benefit
of size and
avoid...
burden
administration
connection to these experts, and
rates are substantiated by actual
Age & zip code
we do not hesitate to lean on them.
claims data from within our trust.
based medical rates
Additionally, our eight full-time
Without this claims performance,
As of August 2015, there are 160 Members
in the Beyond Benefits Trust.
Rising medical premiums in the
employees use member feedback to
any discounted rates or renewals are
industry of 18% vs. Anthem’s
In
an
effort
to
attract
larger
companies
who
8-10%
prepare competitive bids that test
artificial and therefore subject to
typically place out of the Trust with their own
experience rating, Anthem has conceded to
the market, generate more favorable
correction in a subsequent year.
More administrative burden
an aggressive 5-7% rate reduction...
terms, provide member remediation
Additionally, beginning January
WHICH IS A VERY BIG DE AL .
services, ensure supplier compliance
1, 2016, employers with 51 to
Beyond Benefits—a health benefits program exclusive to Biocom
members—gives California Life Science companies of all sizes access to a
and create value for our members.
100 benefits-eligible employees
group health insurance plan designed to provide best-in-class benefits. Since
launching in 2012, Beyond Benefits has saved Life Science companies over
Our board of directors and HR
who are not in the Beyond Benefits
$5M in annual medical premium. Learn how you can become a member
company and start saving: beyond-benefits.org
advisory groups have recently
Trust will be reclassified as ‘small
reviewed the Beyond Benefits
group employers’. This will have a
Trust, evaluated the alternatives in the marketplace and are
tremendous impact and could potentially increase their rates by
quite confident these benefits, provided by Anthem, are the best
30 to 40 percent, depending on size.
available in California. The additional free services and valueThis change is tied to rules that apply to small groups, which are
added resources under this trust, coupled with unmatched pricing,
charged age-based rates. In other words, cost is assessed based
make it the preeminent health insurance choice for any industry
on the age of each employee and spouse in the group. This shift
company.
impacts many employers, especially life science companies that
In just over two years, the trust has welcomed 160 companies,
typically employ between 51 and 100, and adds another obstacle
with a 99 percent retention rate, saving them $5 million in annual
to offering affordable health care.
medical premiums. More importantly, the trust now covers enough
Our board, member advisory committees and hundreds of actively
people and is large enough to withstand claim fluctuations. This
participating member companies could not be more bullish on the
credibility allows the trust to offer substantiated renewal rates well
value of the Beyond Benefits Trust. We are confident you will see
below market standards.
that value continue to improve in the coming years.
The Beyond Benefits Trust will again see single-digit price
NOT
Alternative
14
Biocom LifeLines Fall 2015
Let’s talk.
See how new advances in 1,536-well qPCR are enabling
more biologically relevant high-throughput screening
data using fully automated workflows and multiple
applications with the LightCycler® 1536 System.
For access to presentations,
data and a white paper,
visit go.roche.com/LC1536
or text HTS to 313131
For life science research only.
Not for use in diagnostic procedures.
LIGHTCYCLER is a trademark of Roche.
The LightCycler® 1536 Multiwell Plate is manufactured under license from IT-IS International Ltd.
© 2015 Roche 581-60993-0515
Roche Diagnostics Corporation
9115 Hague Road
Indianapolis, Indiana 46256
COMPLEX PROBLEMS REQUIRE
SOPHISTICATED SOLUTIONS.
For over 160 years, VWR has been growing strong because of our unique
approach to collaborating and encouraging innovation with our customers.
Over time they have been challenged with finding the answers that help improve
lives. Our mission is to enable this by eliminating the process complexities and
identifying product and service solutions that help labs and production facilities
work better, faster, and smarter. Through our global reach and knowledgeable
associates, we proudly excel in delivering solutions that improve productivity,
accelerate discovery, and encourage innovation.
PRODUCT CHOICE. SIMPLIFIED.
VWR enables science by providing our customers the broadest range of choice in quality
products, delivered by a team of people focused on your success.
• Over 2 million products - offering unparalleled choice with best in class brands.
• VWR collection of brands - from everyday products to specialized solutions.
• Custom chemical blends - from our VWR Custom Manufacturing Services.
Together, VWR and Biocom combine our core strengths to offer total solutions that advance scientific
innovation in the life sciences, providing you with substantial cost savings and service solutions to
accelerate science from discovery to production. Extend your purchasing power by taking advantage
of the power of the VWR-Biocom partnership, and realize a total solution platform, so you can focus on
what's truly important: Science.
BIOCOM
INSTITUTE
By Liisa Bozinovic,
Executive Director, Biocom Institute
Never Stop Learning
Talent…people… workforce…staff…employees: these are our
industry’s most important asset. But in the fast-moving biomedical
ecosystem, continuing education is key to retaining that value.
At Biocom, we have provided educational and professional
development opportunities since the beginning. As we celebrate
our 20-year anniversary, we thought it would be fun to take a look
at where graduates from some of our programs are now.
Lab to Leader graduate, Niko Gubernator started as a scientist
without a business background. He had questions about how to
lead people. His company, eMolecules, went from three employees
in 2008 to forty today. Now the company’s CEO, Gubernator
attributes his success as a leader to the team at the Leadership
Edge. Niko reflected, “it is unfortunate how little training scientists
get.” Fortunately, this program helped him quickly learn to better
relate to his employees by being more transparent.
Erick Espinoza, an immigrant from Mexico who was a sophomore
in high school, arrived in the United States seven months before
entering the Life Sciences Summer Immersion Program (LSSI) in
2012. In Mexico, he had taken high school biology and chemistry
courses, but for the first seven months in the United States, he
focused on improving his English. LSSI gave Erick the opportunity
to work on a project at The Scripps Research Institute, which led to
a 3D image of the multi-protein complex SWR1. Understanding the
active sites and functions of that protein has further implications
for the medical field.
The program helped Erick step out of his comfort zone. “I learned
things I never thought I would before, and I not only mastered them
but, gave a presentation to other scientists, parents and teachers,”
said Erick. Today, he is a junior at UC Riverside, studying pre-med
and doing research in astrophysics. More than one of his college
essays incorporated his LSSI experience.
Many veterans have said that transitioning to civilian life is more
difficult than anything they ever did in the military. Amanda Gerber
completed her bachelors in science after her military service. She
even did some work in a lab while going to school. When she
graduated, her goal was to work in a research lab and, living in San
Diego, a lab in a biotech company was appealing to her.
Gerber did not have enough experience for an entry-level
research job until she entered the Biocom Institute’s Veteran
Career Mentoring Program earlier this year. She was paired with
Rich Pascoe, CEO of Apricus Biosciences and also a veteran, and
accepted a program-funded internship with Silicon Biosciences.
The funded internship gave Silicon an opportunity to try out
Amanda as an employee without any financial risks. Amanda is
now a full-time research associate for Silicon and has had an
opportunity to lead her own project, expanding her scientific
knowledge. Our program gave her “the tools to learn how to network
and gain meaningful employment.”
The EDGE program has provided internships for one hundred
participants and training opportunities in biofuels and industrial
biotechnology for hundreds more. Tim Phillips got a job with
Verdezyne less than ten days after finishing the program and has
been promoted from process development technician I to process
development technician II.
Julie Kim credits the EDGE Program with jump-starting her
professional development. Julie completed an internship at
Sapphire Energy in 2011.
“The internship itself was the most valuable aspect of the course,
as it provided hands-on skills in the fast-paced biotech industry
setting. My internship provided me with the experience I needed
to land a job as a full-time associate scientist at a pharmaceutical
company, where I continue to work after 4 years.” Julie currently
works at J&J.
At the Institute, we are passionate about providing access to
quality programs to support both the current and future workforce.
From CEOs to scientists to budding engineers, one thing we all
have in common is that we should never stop learning.
Liisa Bozinovic is the Executive Director of
the Biocom Institute and also heads Biocom’s
HR Initiative.
Professional Development
Biocom LifeLines Fall 2015
17
SCIENCE
FESTIVAL
By Sara Pagano,
Managing Director, SD Festival of Science & Engineering
STEM is the New Trend
You have heard the expression that pink is the new black, well
in the world of research and education, STEM is the new trend.
STEM (science, technology, engineering and math) is accelerating
faster than we can keep up: STEM in sports, afterschool STEM,
STEM pathways, cooking lessons integrating STEM concepts. The
U.S. Department of Education is stressing STEM’s importance to
maintain our global leadership.
“In a world that’s becoming
increasingly
complex,
where
success is driven not only by what
you know, but by what you can
do with what you know, it’s more
important than ever for our youth
to be equipped with the knowledge
and skills to solve tough problems,
gather and evaluate evidence
and make sense of information,”
says the DOE’s STEM web page.
“These are the types of skills
that students learn by studying
science, technology, engineering
and math—subjects collectively
known as STEM.”
Why is STEM so big? Because
of what it means for our future
workforce. How do we keep it
going for future generations?
We start young and look at how
technology is becoming the foundation for STEM learning.
“It appears that STEM-focused learning will continue to be a
top priority in education because of the growing need for a STEMready workforce,” says Tory See, community relations director at
ViaSat. “Beyond the usual STEM careers, we will see technology
integrated into many developing jobs, even those that ordinarily
wouldn’t be considered a STEM career. With the rapid pace of jobs
that are developing to support our changing world, we need to be
ready to teach students in a way that will allow them to adapt to
these changes. Because of this, it is imperative that industry be
supportive of STEM initiatives and education. This support helps
teachers to better understand where industry is currently at and
headed, and enables them to prepare students who STEM career
ready and builds the pipeline of the next generation of workforce.”
The need for students with STEM-related core concentrations
is rapidly growing. These jobs are making an economic impact in
San Diego and around the world. A report from the Georgetown
University Center on Education and the Workforce found that 65
percent of people with bachelor’s degrees in STEM fields earn
18
Biocom LifeLines Fall 2015
more than those with master’s degrees in non-STEM occupations.
In fact, 47 percent of bachelor’s degrees in STEM occupations
earn more than PhDs in non-STEM occupations.
“Qualcomm believes that increasing the number of STEM
graduates, as well as the level of diversity in the talent pipeline, is
the challenge that the entire industry needs to focus on solving,”
says Charles Bergan, vice president of engineering, Qualcomm
Technologies, Inc. “Encouraging
students from elementary to high
school to pursue their interests
in science and engineering is
one of the best ways to ensure
that our technology companies
can continue to innovate in an
increasingly competitive world
market.”
We all know that San Diego
offers a strong foundation for
new company creation and
development. The city continues
to be a catalyst for emerging
young innovators, showcasing that
we can have it all in San Diego: go
to school, conduct research, find
internships and get an amazing
job here to complete the circle
of homegrown workforce that
continues to make an economic
impact. Living in an age of science and technology, STEM affects
our daily lives and will continue to be the driving force behind
future growth. It is crucial that children are inspired, motivated
and educated in STEM.
Do you want to inspire the next generation of innovator? Save the
date for the 2016 San Diego Festival of Science & Engineering.
EXPO Day kicks off on Saturday, March 5, followed by a stellar
week of programming throughout San Diego (March 6-13, 2016).
For more information or to learn more about sponsorship and
exhibitor opportunities, visit www.lovestemsd.org.
Sara Pagano is the Managing Director of the
San Diego Festival of Science & Engineering
**Graphic: U.S. Department of Education
MEMBERS IN ACTION
WE’VE BEEN BUSY: Biocom continues to provide a wide
variety of opportunities for members to come together
and for the Southern California region to highlight
its many attributes. Featured here are a collage of
photos from the September breakfast meeting, the Fire
Side chat with Jay Flatley, Illumina, the Facilities 102
workshop, the BIO International Convention, BIO Japan,
the AdvaMed 2015 MedTech Conference, and the
Biocom Water Workshop.
Photo by J.T. MacMillan Photography
20
Biocom LifeLines Fall 2015
Photo by J.T. MacMillan Photography
MEMBERS IN ACTION
PAC LEGISLATIVE STAFF RECEPTION & BIOCOM PAC LEGISLATORS RECEPTION : The Biocom PAC (Political
Action Committee) is a non-partisan California state committee established to fundraise and
make political contributions to elect candidates and promote issues that will improve the
environment for business and innovation for the life science industry in Southern California.
Biocom PAC contributors (individuals and corporations) enjoy a variety of benefits including
admission to many Southern California political events. The Biocom PAC conducts two annual
signature events, the Biocom PAC Elected Officials Reception and its Legislative Staff Appreciation
Reception, which is the only event of its kind in the area.
Atheln is a Contract Development Organization
delivering solutions to biopharma companies
Innovative virtual product development approach
Multidisciplinary strategy and plans from early stage to exit
Team of industry seasoned experts excel in delivering solutions for risk control
Integration of technical and commercial considerations to maximize product value
www.athelnbiomed.com
monica@athelnbiomed.com / adriana@athelnbiomed.com
310.220.4332
858.554.0636
MEMBERS IN ACTION
BIOCOM OPEN HOUSE: This year marks the 20th anniversary
for Biocom, so we decided to throw a housewarming
party in our new home. Attendees gathered to our new
space on Thursday, October 1st for our Annual Open
House and Purchasing Group Supplier Showcase, as we
did an homage to #throwbackthursday and threw it way
back to celebrate 20 years of success in the life science
community. Attendees networked and mingled amidst
400+ of their life science colleagues, while perusing
the vetted Platinum Suppliers of the Biocom Purchasing
Group to learn about the valuable savings and benefits
exclusively available to Biocom members.
22
Biocom LifeLines Fall 2015
#RadyMade
Scientist
Congrats BIOCOM on
20 Years of Valuable Service
Entrepreneur
“As a scientist turned entrepreneur, my Rady MBA
provided me the business acumen and opportunities
to catapult my entrepreneurial journey. Today, I have
built a female-focused business accelerator and angel
network/fund that has helped launch 56 startups,
facilitated 82 women-owned small businesses to think
big and created over 50 new jobs.”
Silvia Mah, Ph.D., MBA ‘10
CEO, Hera Labs & Founding Partner, Hera Fund
I am RadyMade
NEVER STOP STARTING UP
To see more stories:
rady.ucsd.edu/radymade
MBA | MFIN | MSBA | Ph.D. | ExecEd
SAVE THE DATE: Biotech Demystified - September 12-14, 2016
Percent of total GeneTests genes covered
Reveal Greater Coverage
Depth in WES
60.0
Roche MedExome
Supplier A's Clinical Research Exome
50.0
40.0
30.0
20.0
10.0
0.0
<90%
90-97%
97-100%
100%
Percent of each GeneTests gene’s coding bases covered at ≥20X
Figure 1. With SeqCap EZ MedExome, 53% of
medically relevant genes are covered at 100%
(≥20X coverage) vs. 6% by Supplier A’s Clinical
Research Exome. Percentage of bases covered at
≥20X for each consolidated target was determined
using GATK (DepthOfCoverage), summarized by gene.
Supplier A kit’s data was generated by a third-party
sequencing service provider, following Supplier A’s
protocol. All reads were subsampled to 60 million for
assessment, then subjected to the same bioinformatics
pipeline for analysis. Roche data on file.
For life science research only.
Not for use in diagnostic procedures.
NIMBLEGEN and SEQCAP are trademarks of Roche.
© 2015 Roche 581-61699-0915
Achieve greater coverage depth from less sequencing through the
enhanced coverage of the new SeqCap EZ MedExome Target
Enrichment Kit for whole exome sequencing (WES). Rely on a design
developed to enrich the entire exome, but particularly optimized for
analyzing genes of medical relevance (Figure 1) in research studies.
• Focus on genomic regions that really matter
For disease-associated genes, 98% of bases are covered at ≥20X depth.
• Call variants with confidence
Detect SNPs with 98% sensitivity and >99% specificity for SNP allele
classification.
• Gain greater efficiency at minimal cost
Reduce sequencing cost through uniform coverage and fully supported
multiplexing protocols.
Reveal more about the exome
Learn more about how the SeqCap EZ MedExome Target Enrichment
Kit can improve your whole exome sequencing by visiting
sequencing.roche.com/medexome.html or calling 800-262-4911.
Roche Diagnostics Corporation
9115 Hague Road
Indianapolis, Indiana 46256
PURCHASING
GROUP
By Rick Fultz,
Managing Director, Biocom Purchasing Group
Member Driven Evolution
As Biocom celebrates our 20th year as Southern California’s
premier, member-driven life science industry association, we at
the Biocom Purchasing Group can’t help but reflect on how far
we’ve come since our very modest beginnings.
What began as a small group of life science companies coming
together to negotiate terms for basic lab supplies has grown into
a vehicle with global reach that now generates $120 million in
member savings each year.
With offerings that include lab supplies, office supplies, specialty
gases, shipping, travel and health insurance, companies can find
many ways to take advantage of the program. Most are saving 15
to 25 times their annual membership dues.
By leveraging hundreds of millions of dollars in collective
spending and providing Biocom Purchasing Group suppliers with
opportunities to enhance their organizations, we can negotiate
price points that consistently beat national group purchasing
organizations (GPOs) like Premier, Novation, Med Assets, Core
Trust and others.
In addition to discounts and services, industry companies can
leverage our systems and staff to assist them (free of charge)
with contract compliance, due diligence, quality assurance and
market assessment. Our compliance team tracks all Purchasing
Group contracts and closely monitors our formal Member
Feedback Program. They meet regularly with members and
operate as a neutral, third-party advisor, translating feedback into
solutions and building trust every step of the way. Additionally,
member companies can find assistance with conflict mediation,
procurement and supply chain best practices, as well as gain
access to industry educational seminars and enhanced member
collaboration.
Our members are engaged at every level: from the committees
that select and oversee our contracts to the board that steers the
direction of the organization. It is this comprehensive participation
that has made the Biocom Purchasing Group a trusted advisor and
industry leader in life science operational success.
This evolution of the Biocom Purchasing Group also comes with
great responsibility. We are representing one of the most powerful
and influential life science industries in the nation, and we owe
it to our members to negotiate outstanding contracts with leading
service providers. Biocom members are no longer satisfied with
mediocre price concessions, nor will they stand for anything short
of best-in- class customer service and dedicated, Biocom memberonly resources.
As a result of this clout, our high-caliber request for proposal
(RFP) process has dramatically strengthened over the last few
years. Our member-driven RFPs are our backbone and serve as an
ongoing clearinghouse for life science industry trends.
In recent years, we have leveraged this world-class combination
of human capital, knowledge and combined spending to secure
a first-of-its-kind life science healthcare trust, an international
travel program, nationally-competitive office product and furniture
contracts and a one-of-a-kind garment and cleanroom contract. In
2016, we will deliver an industry-changing lab supply contract,
industrial gas contract, global shipping agreement and several
other new contract areas.
Increasing the depth of our due diligence has been key to our
evolution as the most valued group purchasing organization in the
world. We strive to better serve our membership and create the
robust portfolio of savings that will lead to success for our member
companies. To be a part of this exciting evolution in 2016, please
contact any one of our Biocom Purchasing Group staff for more
information.
Rick Fultz oversees membership and
sponsorship efforts, business development
opportunities, and the Biocom Purchasing
Group.
Biocom LifeLines Fall 2015
25
PREMIUM MEMBER SPOTLIGHTS
PREMIUM MEMBERS
AbbVie
Airgas
Aldevron
Alexandria Real Estate Equities
Althea
Arena Pharmaceuticals
Bayer Healthcare
Biogen
Biomed Realty Trust
Biospace
Bridge Bank*
California Manufacturing Technology
Consulting
Canale Communications
Celgene
City National Bank
COI Pharmaceuticals
Conatus Pharmaceuticals
Cooley LLP
Deloitte
DLA Piper
Dowling & Yahnke*
Eli Lilly
Ernst & Young
Evaluate Pharma
Ferring Research Institute
Fisher Scientific
GE Healthcare Life Sciences
Genoptix
Hologic
J-Labs
Jones Day
KPBS
KPMG
Latham & Watkins
Mallinckrodt Plc
Mentus
Merck Research Laboratories of San Diego
Mintz, Levin, Cohn, Ferris, Glovsky and
Popeo
NuVasive
Office Depot
Pfizer
Prometheus Laboratories
PwC
Thermo Fisher Scientific
Unisource Solutions
VWR International
Wilson Sonsini Goodrich & Rosati
* New Members from May 2015 to October 2015
www.biomedrealty.com
Name: Tracy Murphy
Job title: Regional Vice President, San Diego
Favorite movie: Old School
Favorite books: Winning by Jack Welch
Favorite quote: “Individual commitment to a group effort – that
is what makes a team work, a company work, a society work, a
civilization work.” – Vince Lombardi
Favorite TV show: CBS Sunday Morning
Favorite restaurant or meal: Qero, Encinitas
Favorite city: US: Chicago EU: Amsterdam
Favorite actor/actress: Matt Damon/Christina Applegate
Favorite thing to do on the weekends: any sport with my boys
What CD can we find in your car: Kygo
Favorite hobby: Painting
26
Biocom LifeLines Fall 2015
Favorite website: OfficeSnapShots
Favorite spot in Southern California: Pony Room @ Rancho Valencia
First job: Pre-College – Art Gallery, Post-College -Marketing Director BRE Commercial
(recently acquired by Cushman Wakefield)
Favorite part of your job: Strategy of Repositioning Assets
If you could have another career, what would it be: Interior Designer
Why did you start working in your industry: Through real estate specific to the life science
industry, I felt like I could support the brightest minds pursuing change in the most
important causes.
Abzena expands into Southern California
The Abzena group has undergone a significant transformation in the past few years
following the acquisition of Antitope in 2013 and PacificGMP in 2015. Bringing together
these companies allows Abzena to support customer’s projects seamlessly from lead
selection through to GMP manufacturing for clinical trials.
San Diego, USA
Now enabling better biopharmaceuticals from more locations.
GMP manufacturing that specializes in single-use
technology for the production of biopharmaceuticals
for Phase I and Phase II clinical trials
Process development focuses on improving
yield at each stage of development by
optimizing each step in the process
Coventry, UK
R&D site for developing and synthesising
conjugation and PEGylation reagents
PolyPEG™ a low viscosity polymer to
make it easier to manufacture and inject
long-acting therapeutic proteins
Cambridge, UK
iTope and TCED™ to identify T cell epitopes
using a proprietary database and algorithm
Biosimilar cell line development in CHO,
NS0 and SP2/0 including enhanced PQA
EpiScreen™ for ex vivo assessment of the
immunogenicity of biopharmaceuticals
ThioBridge™ for the generation of more
homogeneous antibody drug conjugates
Composite Human Antibody™ technology
to humanise and deimmunise antibodies
TheraPEG™, CyPEG™ and HiPEG™ for
linking polymers to therapeutic proteins to
extend their duration of action
Composite Protein™ technology for
deimmunisation of therapeutic proteins
Composite CHO™ to produce high
expressing cell lines for manufacture
Start your project today. Visit www.abzena.com
PREMIUM MEMBER SPOTLIGHTS
www.bridgebank.com
Your Name: Rob Lake
Job title: SVP, Head of Life Sciences
Favorite movie: TRemember the Titans
Favorite book: Tuxedo Park by Jennet Conant
Favorite quote: “I learned that courage was not the absence of fear,
but the triumph over it. The brave man is not he who does not feel
afraid, but he who conquers that fear.” – Nelson Mandela
Favorite TV show: Seinfeld
Favorite restaurant or meal: Gramercy Tavern in NYC
Favorite city: Chicago, IL (during the summer) and San Diego, CA (all other times)
Favorite actor/actress: Robert De Niro / Gwyneth Paltrow
Favorite thing to do on the weekends: Spend time with family (my wife, 4-year old boy, and
6-month old girl) & friends
What CD can we find in your car: Hullabaloo (I lost control of the music selection a couple of
years ago.)
Favorite hobby: Home improvement
Favorite website: Amazon.com
Favorite spot in Southern California: Del Mar Beach
First job: Weekend shift at White Castle
Favorite part of your job: Coming up with creative solutions to help people solve complicated
problems.
If you could have another career, what would it be: Medical Doctor
Why did you start working in your industry: It was intriguing to be able to apply my skills in
commercial finance to the life sciences sector. For me personally, doing what I do is not only
a job and a career, it’s philanthropic. It feels good to be able to help life sciences companies
with their financial needs in a concerted effort to save and improve peoples’ lives.
new
discoveries
start
HERE
ASCB 2015 is your direct line to the most innovative and exciting research being
done in basic cell biology today. Our researchers—the top minds in life sciences—are
moving the needle in biophysics, neuroscience, cancer biology, immunology, synthetic
biology, and bioinformatics. Use this extraordinary opportunity to connect with those
on the cutting edge of applied discovery. The best patents come from the best basic
research. The best basic research will be presented at ASCB 2015.
We want to see you at our meeting, so we’re being flexible! New this year, ASCB
is offering one-day registration, to better accommodate your schedule. It’s more
convenient and inexpensive than ever to participate in our meeting!
EXHIBIT BOOTHS STILL AVAILABLE
ascb.org/2015meeting
/ascbiology
@ascbiology
#ascb15
ascb
PREMIUM MEMBER SPOTLIGHTS
www.dywealth.com
Name: Brett Pernicano
Job title: Portfolio Manager
Favorite movie: The Boondock Saints
Favorite books: The Great Gatsby by F. Scott Fitzgerald
Favorite quote: “It takes 20 years to build a reputation and only
five minutes to ruin it” – Warren Buffett
Favorite TV show: Not big on shows but love ESPN “30 for 30”
Favorite restaurant or meal: I have to stick with my family roots
on this one. Pernicanos Pizza.
Favorite city: Born and raised in America’s Finest City San Diego
Favorite actor/actress: Jack Nicholson
Favorite thing to do on the weekends: Assuming I have the time, I love to play beach
volleyball
What CD can we find in your car: Who owns CD’s (compact discs) anymore?
Favorite hobby: Golf would definitely be at the top of the list
Favorite website: The Wall Street Journal (www.wsj.com)
Favorite spot in Southern California: Any beach from San Diego north to Santa Barbara
First job: I had the distinguished pleasure of working as a driving range assistant at The
Meadows Del Mar Golf Course (aka The Grand Del Mar)
Favorite part of your job: The ah-ha moment in a client meeting where the portrait I paint
for my clients is actually seen.
If you could have another career, what would it be: A surgeon. Since I was a kid I have always
wanted to get into the medical field.
Why did you start working in your industry: Once I purchased my first mutual fund at the age
of 16 I knew I was hooked. When I found a profession I could help people while working
with investments it was a perfect match.
www.vwr.com
Name: Charles McWilliams
Job title: Vice President, Strategic Alliances
Favorite movie: It’s hard to pick one. When I very young I would
have said “Star Wars”
Favorite books: TI don’t think that I have one, but I enjoyed
almost all of Michael Chrichton’s books
Favorite quote: Persistence from Calvin Coolidge “Nothing in this
world can take the place of persistence. Talent will not; nothing
is more common than unsuccessful men with talent. Genius
will not; unrewarded genius is almost a proverb. Education will not; the world is full of
educated derelicts. Persistence and determination alone are omnipotent. The slogan Press
On! has solved and always will solve the problems of the human race.”
Favorite TV show: I really don’t watch TV, but I recently watched, and really loved Band of
Brothers
Favorite restaurant or meal: Wahoo’s Fish Tacos
Favorite city: Rome
Favorite actor/actress: John Wayne
Favorite thing to do on the weekends: A day at the beach with family and friends
What CD can we find in your car: I don’t have CD’s but have a wide music taste that ranges
from current top hits to hip hop. Anything but country.
Favorite hobby: Do people listed to CDs any more? I listen to Pandora, and it’s based on
my mood
Favorite website: Netflix
Favorite spot in Southern California: Abalone cove
First job: Courtesy Clerk in Grocery Store
Favorite part of your job: Working with great people
If you could have another career, what would it be: I had always wanted to be an Astronaut.
It seems far fetched, but if I could could do one thing that would still be it.
Why did you start working in your industry: I set out intending to work in a tech company, but
I found something much better in the LifeSciences!
BIOCOM SPOTLIGHT
Name: Melanie Nally
Job title: Associate Director of Local Government
& Regulatory Affairs
Favorite movie: Amelie
Favorite books: The Fountainhead
Favorite quote: “Your time is limited, so don’t waste it living
someone else’s life. Don’t be trapped by dogma – which
is living with the results of other people’s thinking. Don’t
let the noise of other’s opinions drown out your own inner
voice. And most important, have the courage to follow your heart and intuition. They somehow
already know what you truly want to become. Everything else is secondary.” - Steve Jobs, 2005
Stanford Commencement Address
Favorite TV show: Sons of Anarchy
Favorite restaurant or meal: Urban Solace
Favorite city: Paris
Favorite actor/actress: Edward Norton/Keira Knightley
Favorite thing to do on the weekends: Explore new restaurants and breweries
What CD can we find in your car: Ray LaMontagne
Favorite hobby: Traveling
Favorite website: www.manrepeller.com
Favorite spot in Southern California: North Park
First job: Taco Bell
Favorite part of your job: Working hands-on with elected officials and regulators to create
policies that positively impact our members.
If you could have another career, what would it be: Fashion buyer
Why did you start working in your industry: I was introduced to Biocom by Jimmy Jackson in 2005
and have wanted to work for him ever since (seriously!). I was working for an elected official at
the time, and was drawn to the industry because of everything it does to alleviate disease and
advance medical care.
Biocom LifeLines Fall 2015
29
BOARD OF DIRECTORS
BOARD OFFICERS AND EXECUTIVE COMMITTEE:
CHAIR: Theodore Schroeder*
VICE CHAIR: Carin Canale-Theakston, Canale Communications*
CHAIR ELECT: Daniel Burgess*
VICE PRESIDENT AND GENERAL COUNSEL: Lisa Haile, Ph.D., DLA Piper*
VICE PRESIDENT – FINANCE: Daniel Kleeburg, Ernst & Young*
VICE PRESIDENT – INDUSTRY: Christophe Schilling, Ph.D., Genomatica, Inc.*
VICE PRESIDENT AND SECRETARY: Brent D. Jacobs, Cushman & Wakefield*
CHAIR EMERITUS: Magda Marquet, Ph.D., Althea (A member of the Ajinomoto Group)*
PRESIDENT & CEO: Joe Panetta, Biocom*
Vincent Anido, Ph.D., Aerie Pharmaceuticals
Steven Bartz, Ph.D., Merck & Company
Scott Biel, Mintz, Levin, Cohn, Ferris, Glovsky & Popeo
Michael Boyd, AbbVie
Michael Brown, Stradling Yocca Carlson & Rauth
Terrance J. Bruggeman
Carol Cox, NuVasive
John M. Dunn
Stephen Ferruolo, J.D., Ph.D., USD School of Law*
Oliver Fetzer, Ph.D., Synthetic Genomics
M. Wainwright Fishburn, Jr., Cooley LLP*
Don Fitzgerald, Genentech
Jack Florio
Gregory Fond, Sanofi Global R&D
Gregory Frost
Carol Gallagher
Jeffrey W. Guise, Ph.D., Wilson, Sonsini, Goodrich & Rosati
Richard Heyman, Ph.D.
Elliot Hirshman, Ph.D., San Diego State University
Matthew Hudes, Deloitte LLP
Guy J. Iannuzzi, Mentus
Gerald Joyce, M.D., Ph.D., Genomics Institute of the Novartis Research Foundation
David Kabakoff, Ph.D., Sofinnova Ventures
Katherine Kantardjieff, Ph.D., California State University San Marcos
Paul Laikind, Ph.D., ViaCyte
Jacob Levin, Ph.D., UC Irvine
James Levine, Sapphire Energy*
Jack Lief*
John Lister, Dexcom
Damien McDevitt, Ph.D., GlaxoSmithKline
Steven Mento, Ph.D., Conatus Pharmaceuticals, Inc.*
William Molloie, PwC
Tracy Murphy, Biomed Realty Trust
Paul Negulescu, Ph.D., Vertex Pharmaceuticals, Inc.*
Perry Nisen, M.D., Ph.D., Sanford-Burnham Medical Research Institute
Brian O’Callaghan
Kenneth Polin, Jones Day
Trindl Reeves, Barney & Barney LLC*
Gregory Reyes, M.D., Ph.D., Celgene
Dan Ryan, Alexandria Real Estate Equities
Camille Saltman, Malama Composites, Inc.
James Schaeffer, Ph.D., Calibr*
Timothy Scott, Pharmatek*
Bhasker Shetty, Ph.D., Pfizer La Jolla
Larry Stambaugh, Kalos Therapeutics*
Mark Stevenson, Thermo Fisher Scientific*
Tsuneo Takahashi, NF Corporation
Scott N. Wolfe, Latham & Watkins
LIFE DIRECTOR:
Kennon W. Baldwin, Ferguson Pape Baldwin Architects*
David Hale, Hale BioPharma Ventures*
Tina Nova, Ph.D., Molecular Stethoscope
Biocom Board Members-Ex-Officio:
Sandra Brown, Ph.D., UCSD
Mark Cafferty, San Diego Regional Economic Development Corporation
Constance Carroll, Ph.D., San Diego Community College District
Scott Lippman, MD, Moores Cancer Center, UCSD
Greg McKee, CONNECT
Peter Preuss, The Preuss Foundation
Jerry Sanders, San Diego Regional Chamber of Commerce
David Webb, Ph.D., Scripps Research Institute
*Executive Committee Member
COMMITTEE LEADERSHIP
BIG DATA
Larry Smarr, Cal(IT)2
Biocom Institute Board Committee*
Steven J. Mento, Ph.D., Conatus Pharmaceuticals, Inc.
Capital Development Committee*
Carin Canale-Theakston, Canale Communications
David Kabakoff, Ph.D., Sofinnova Ventures
CRO Committee
Timothy Scott, Pharmatek
Environmental, Health and Safety Committee
Cliff Hanna
Dan Shiel, Pfizer La Jolla
Facilities Committee
Andy Darragh, Ferguson Pape Baldwin Architects
Brent D. Jacobs, Cushman & Wakefield
30
Biocom LifeLines Fall 2015
FDA Committee
Magda Marquet, Ph.D., Althea (A member of the
Ajinomoto Group)
Michele Yelmene
Intellectual Property and Patent Law Committee
Daniel Hart, Knobbe Martens Olson & Bear LLP
Michael Mueller, Conatus Pharmaceuticals
International Committee
Kenneth Polin, Jones Day
Legislative Committee
Richard Ledford
April Grant, Sunovion Pharmaceuticals
Medical Device Committee
Mike Oliver, Spectra Science
Joleen Schultz, Rady School of Management, UCSD
Digital Health Committee
Apurv Kamath, Dexcom
Public Policy Oversight Committee*
Larry Stambaugh, Kalos Therapeutics
Paul Laikind, ViaCyte
Purchasing Board Committee*
Jack Lief
Veterans Committee
Josh Vosovic
*Board Level Committees
BIOCOM MEMBERSHIP
PREMIUM
Bridge Bank*
California Manufacturing
Technology Consulting
Canale Communications
Celgene
City National Bank
COI Pharmaceuticals
Conatus Pharmaceuticals
Cooley LLP
Deloitte
DLA Piper
Dowling & Yahnke*
Eli Lilly
Ernst & Young
Evaluate Pharma
Ferring Research Institute
Fisher Scientific
GE Healthcare Life Sciences
Genoptix
Hologic
J-Labs
Jones Day
KPBS
KPMG
Latham & Watkins
Mallinckrodt Plc
Mentus
Merck Research Laboratories of
San Diego
Mintz, Levin, Cohn, Ferris,
Glovsky and Popeo
NuVasive
Office Depot
Pfizer
Prometheus Laboratories
PwC
Thermo Fisher Scientific
Unisource Solutions
VWR International
Wilson Sonsini Goodrich &
Rosati
3-V Biosciences*
Abcore
Abgent
Abide Therapeutics
Abilita Bio
Abwiz Bio
ACADIA Pharmaceuticals
ActivX Biosciences
Advanced BioMatrix
Advanced Targeting Systems
Aerie Pharmaceuticals
Agena Bioscience
Aimmune Therapeutics*
Ajinomoto Pharmaceuticals
AM Chemicals
Ambryx Biotechnology
Amgen
Amicrobe
Amplyx Pharmaceuticals
AnaptysBio
Animal Cell Therapies*
Ansun Biopharma
Apricus Biosciences
Aptose Biosciences*
Aratome*
Arcturus Therapeutics
Arcus Bioscience*
Ardea Biosciences
Armetheon*
Arrayomics
Arytha Biosciences
Asahi Kasei Pharma*
Astellas Pharma
aTyr Pharma
Auspex Pharmaceuticals
Avantgen
Avelas
Avidity NanoMedicines
Aviva Biosciences
Bachem Americas
BASF
Beloteca*
BioLegend
Biomatrica
Biomyx
BioNano Genomics
Bionomics
Bio Options
BioSpyder Technologies
BioWa
Boehringer-Ingelheim
Curtana Pharmaceuticals
CalciMedica
CannaVest Corporation
Cell Applications
Celladon
Cellana
Center for Aquaculture Technologies
Channel Medsystems*
Chubu Technology Licensing Office
Cibus
Cidara Therapeutics
Coda Therapeutics
Conju-Probe
Contract Biotics
Cosmederm Bioscience
Crinetics Pharmaceuticals
Cypher Genomics
CytomX Therapeutics*
Dart Neuroscience
Definiens
Dermata Therapeutics*
Diomics Corporation
DNA Link USA
DNAtrix
DSM Food Specialties
E&B Technologies
Edico Genome
eFFECTOR Therapeutics
Elcelyx Therapeutics
Electronic BioSciences
eMolecules
Epeius Biotechnologies
Epitracker*
Equitech Bio
Eton Bioscience
Fabrus
Fate Therapeutics
Forge Therapeutics
Genelux Corporation
Genentech
Genlantis
Genoa Pharmaceuticals
Genomatica
Genovo Corporation
GenSignia Life Sciences
GigaGen
GlaxoSmithKline
Global Medical & Research
Technologies
GWR Instruments
Halozyme Therapeutics
Helix*
Heron Therapeutics*
Histogen
Human Longevity
Huya Bioscience International
IDEXX BioResearch
Illumina
Imprimis Pharmaceuticals
Inception Sciences
Indi Molecular
Inhibrx
InnoPep
Innovative Cell Technologies
Innovus Pharmaceuticals
Inovio Pharmaceuticals
Integrated DNA Technologies
Intercept Pharmaceuticals
International Stem Cell
Intrexon Corporation
Intrinsic LifeSciences
Invetech
InvivoGen
IRBCo.
ISIS Pharmaceuticals
J-Oil Mills
JSR Micro
Kalos Therapeutics
Kalyra Pharmaceuticals
Koltan Pharmaceuticals
Kura Oncology
Kyowa Hakko Kirin California
La Jolla Biologics
La Jolla Pharmaceutical Company
Ligand Pharmaceuticals
Laguna Pharmaceuticals*
Leading Biosciences*
Lion Biotechnologies*
Lpath
Lumena Pharmaceuticals
MabVax Therapeutics
Malama Composites
Mast Therapeutics
MDRejuvena
MEI Pharma
Meiji Seika Pharma
Metacrine*
Mirati Therapeutics
Molecular Stethoscope*
Monsanto
MultiVir
Nagano Science USA*
Nautilus Environmental
Neothetics
NeuroGenetic Pharmaceuticals
NF Techno Commerce
Nitto Denko Technical
Novartis Pharmaceuticals
Novo Nordisk
Nucelis
OBI Pharma USA
Ocera Therapeutics
Ohr Pharmaceuticals
Optimum Therapeutics
Orexigen Therapeutics
OrPro Therapeutics
Otonomy
Oxford Bio Therapeutics*
Pacira Pharmaceuticals
Panmira Pharmaceuticals
Patara Pharma
Pathway Genomics
PersImmune
Pfenex
PharmAkea
Polaris Group
Polynoma
PolyPeptide Group
Poseida Therapeutics
Predictive Biology
PrimeGen Biotech
Primordial Genetics
Prognosys Biosciences
ProSci
QED Bioscience
Quanticel Pharmaceuticals
Receptos
Regulus Therapeutics
REKA Health
Rempex Pharmaceuticals
Renova Therapeutics
Ribomed Biotechnologies
Ridgeline Engineering
RIFT Biotherapeutics*
Roche Applied Science
Rohto Pharmaceutical
RQX Pharmaceuticals
RuiYi
Sapphire Energy
Samumed
Samsara Sciences
Sanofi
Scilex Pharmaceuticals*
Scripps Laboratories
Senior Scientific
Senju USA
Senomyx
Senté
Seragon Pharmaceuticals
SGB
Silicon Biosystems
Sirenas Marine Discovery
Solstice Biologics
SomaLogic
Sophiris Bio
Sorrento Therapeutics
SOVA Pharmaceuticals
Sparsha Pharma USA
Stemedica Cell Technologies
StemImmune
StemoniX*
StemProtein*
Sunovion Pharmaceuticals
Synthetic Genomics
Takeda Pharmaceuticals U.S.A.
Tanabe Research Laboratories
Tarere Therapeutics*
TEGA Therapeutics
Tenova Pharmaceuticals
Thesan Pharmaceuticals
Tocagen
Tonbo Biosciences
TP Therapeutics
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Triphase Accelerator
Triton Health & Nutrition
UCB
US Specialty Labs
Vantari Genetics
Vaxiion Therapeutics
Verdezyne
Vertex Pharmaceuticals
Vet-Stem
ViaCyte
Vical
Viking Therapeutics
Visionary Pharmaceuticals
Vital Therapies
Wellspring Biosciences
Wildcat Discovery Technologies
World Fusion US
Xencor
Yokogawa Electric*
AbbVie
Airgas
Aldevron
Alexandria Real Estate Equities
Althea
Arena Pharmaceuticals
Bayer Healthcare
Biogen
Biomed Realty Trust
Biospace
* New Members from May 2015 to October 2015
Biocom LifeLines Fall 2015
31
BIOCOM MEMBERSHIP
CRO/CMO
Bavarian Nordic*
Behavioral Pharma
Bend Research
BioAtla
BioBlocks*
Bioserv Corporation
BTS Research
CalChem Synthesis
Cassia
Cato Research
Champions Oncology*
Charles River Laboratories
ChemDiv
ChemPartner*
Cleave Biosciences*
Clintec International*
Combi-Blocks
Concortis Biosystems
Crown Bioscience San Diego
Cytelligen
Davos Chemical
DD Studio
Drug Delivery Experts
eStudySite
Evotec*
Exon BioSystems
Explora BioLabs
Formex
Genea Biocells*
Global Blood Therapeutics*
GRAM Laboratories
Hamari Chemical San Diego Research
Center
HD Biosciences
Huntingdon Life Sciences
IMS Health
Integrium Clinical Research
inVentiv Health Clinical
IriSys
iXCells Biotechnologies USA
JadeBio
KaloBios Pharmaceuticals*
Mediconomics
MicroConstants
Molecular Response
MPI Research
MS Clinical Services*
My Chem LLC
Neuroservice
Neuro-Sys
Outerspace Design Group
Pacific Rim Pathology*
PacificGMP
PharPoint Research
PharmaDirections
Pharmatek Laboratories
PrimaPharm
Profil Institute for Clinical Research
PSI CRO
Puracyp
Quadrants Scientific
Reveal Biosciences
Rho
Robarts Clinical Trials
Roowin
SAFC Pharma
Sherpa Clinical Packaging
Spaulding Clinical Research
Starfish Medical
SynteractHCR
Therapeutics, Inc.
Tioga Research
Toxikon
Triligent International
Ultimate Labs
VIRAPUR
Wax-It Histology Services
WuXi AppTec
Zensun USA
Zyagen
MEDIC AL DEVICE &
DIAGNOSTIC
Cell Idx
CeloNova BioSciences
Celula
Cliniqa Corporation
ClinMet
CombiMatrix
Compellon
Critical Diagnostics
CTK Biotech
CVAC Systems
Cytori Therapeutics
DermTech International
DexCom
Diagnostic Consulting Network
Dorsa Vi USA
Ellipse Technologies
Emerge Diagnostics
Endologix
Enigma Diagnostics
Entra Health
Epic Sciences
Epitope Diagnostics
Fallbrook Engineering
FemCap
Fortimedix USA
Freedom Meditech
GenomeDx Biosciences
GenWay Biotech
GIMDx
Glaukos Corporation
Glysens
Hitachi Chemical Research Center
Hygeia Medical
Ichor Medical Systems
Ignyta
ImpediMed
ImThera Medical
Inari Medical
Inceptus Medical
INOVA Diagnostics
Interpreta
Interventional Spine
InVision Biomedical Group
Invivoscribe Technologies
Ionian Technologies
Ivantis
KFx Medical
Lumira*
MARDX Diagnostics
Medipacs
Micell Technologies
Millennium Health
Nano Imaging Services
Nanomedical Diagnostics
NuFACE
Omniome
OncoSec Medical
Organovo
Parallel 6
Pediatric Bioscience
Prometheus Laboratories
Qualigen
Quidel
Quinn Medical
ReCor Medical*
ReShape Medical
REVA Medical
ReVision Optics
Roka Bioscience
SeaSpine Orthopedics*
Sequenom
Sequent Medical
Sienna Labs
Signal Genetics*
Sirigen
Solekai Systems*
Sonendo
SpectraScience
Spinal Elements
Suneva Medical
Tandem Diabetes
Targeson
TherOx
Tristan Technologies
Trovagene
Uptake Medical
Vention Medical*
Yulex
NON-PROFIT
Human BioMolecular Research
Institute
Institute of Engineering in Medicine
ISM San Diego
J. Craig Venter Institute
Kaiser Permanente
La Jolla Bioengineering Institute
La Jolla Institute for Allergy &
Immunology
Lawrence Family Jewish Community
Center
Los Angeles Biomedical Research
Institute
MiraCosta College Biotech Program
Mt. San Jacinto College
PhRMA
Point Loma Nazarene University
PRISM*
Rady School of Management, UCSD
Salk Institute For Biological Studies
San Diego Biomedical Research
Institute
San Diego Blood Bank
San Diego Clinical and Translational
Research Institute, UCSD
San Diego Community College District
San Diego County Water Authority*
San Diego Employers Association
San Diego Regional Chamber of
Commerce
San Diego Regional Economic
Development Corp.
San Diego Supercomputer Center
(UCSD)
San Diego Workforce Partnership
Sanford-Burnham Medical Research
Institute
Scottish Development International
Scripps Health
Scripps Research Institute
The BioIndustry Association
The Lowy Medical Research Institute
(LMRI)
Torrey Pines Institute for Molecular
Studies
UC San Diego Extension
UCI’s Office of Research
UCSD, Department of Bioengineering
UCSD School of Medicine
UCSD, Technology Transfer Office
UK Trade & Investment
University of San Diego
INDIVIDUAL
3DT Holdings
Abbiotec
ABL
Absorption Systems
Accelagen
Accugent Laboratories
Acurian
Advantar Laboratories
Advin Biotech*
Agility Clinical
Alkahest*
Alliance Protein Laboratories
A&M Biomedical
American Peptide Company
AnaBios
Animantis
Annova Chem
ARIANNE
Atheln
Acon Laboratories
Aethlon Medical
Alphatec Spine
AltheaDx
Amydis Diagnostics
Applied Proteomics
Astute Medical
Axonics Modulation Technologies
Banyan Biomarkers
BeneChill
Biocept
BioDx
Biological Dynamics
Biomerica
Biospacific*
bioTheranostics
Bio Trace Medical*
Breathe Technologies
Bruin Biometrics
Burl Concepts*
American Cancer Society, Border
Sierra Region
Battelle
Calibr
California Baptist University, College of
Engineering
California Medical Innovations
Institute
California State University, Fullerton*
California State University, San Marcos
Case Western Reserve, School of
Engineering
CIRM
City Of Murietta
CONNECT
Consulate Of Canada
CSU, CSUPERB Program
32
Biocom LifeLines Fall 2015
Antoinette Azevedo
Bernard King
Carol Gallagher
Decky Goodrich*
Donna Janson
Elliot Parks
Gary Friedman
John Kavanagh
Julie Ames
Mike Van Horn*
Peter Preuss
Richard Ledford
Stan Kim
Tom Murphy*
KEY PROVIDER
Barney & Barney
Cushman & Wakefield
Foley & Lardner*
Qualcomm
San Diego Gas & Electric
PROVIDER
2Connect
Accelrys
AER Travel
AIS Data Centers
Alexander’s Mobility Services
Alliant Insurance
AMN Healthcare
Assay Depot
Bank of America
Beckloff Associates
Bente Hansen & Associates
Bionest Partners
BioSurplus
Biotech Primer
Biotech Vending
Biotechnical Services*
BioTix
Blue Sky Broadcast
Brizzey
Caliber Associates
California Commercial Security
Cambridge Research Biochemicals
CBRE
Central Pharma Contract Packaging
Chubb Group of Insurance Companies
Clinigen Healthcare
Coastal Payroll Services
Controlled Contamination Services
Corning
CORT*
Cox Business
CryoPort*
CSM*
Cymer
Domain Associates
DPR Construction*
Elsevier
EquipNet
Euretos
Ferguson Pape Baldwin Architects
Fisher & Phillips
Forward Ventures
Fragomen, Del Rey, Bernsen & Loewy
French Biobeach
Frequentz
Grande Colonial
Green Charge Networks
Gunderson Dettmer
Hartl Team- Private Banking &
Investment Group- Merrill Lynch
Haworth
HCP Life Science Estates
H.G. Fenton Company
Hyatt Regency La Jolla at Aventine
Innovative Lease Services
J.T. MacMillan Photography
Jackson & Blanc HVAC Contractors
Jones Lang LaSalle
Kilroy Realty
Knobbe, Martens, Olson & Bear
Leadership Edge
Legacy Partners Commercial
Leverage Concierge*
Life Science IT
Lonza AG
Managed Laboratory Services
Managed Solution
Mayer Hoffman McCann
McKenna Long & Aldridge
Medline Industries
Michael Ehrenfeld Company*
Morrison & Foerster
Newhoff Healthcare Communications
Objective Capital Partners*
Occupational Services
Orion International Patent Office
Oxford Finance
Pharmour
PR Newswire
Prevost Construction
Procopio, Cory, Hargreaves & Savitch
Project Management Advisors
Prudential Cleanroom Services*
Retirement DNA
Sartorius
Savills Studley
SecureDocs*
Scient Federal Credit Union
Sharp Business Systems
Sheppard Mullin Richter & Hampton
Shred San Diego
Signature Analytics
Silicon Valley Bank
Sofinnova Ventures
Sonceboz Corporation
Speid & Associates
Springer Science & Business Media*
Square 1 Bank
Stradling Yocca Carlson & Rauth
Surplus Solutions
Technical Safety Services
The HealthEd Group
Thomas, McNerney & Partners
Time Warner Cable
TriNet*
Troutman Sanders*
TUV SUD America*
Unanet
Unifirst
United Parcel Service (UPS)
Vault Bioventures
VDP Direct
Veolia
WCCT Global
* New Members from May 2015 to October 2015
HELPING
INNOVATION
THRIVE.
With more than 300 legal professionals operating in over
25 countries, our Life Sciences practice handles some of the most
complex, high-profile life sciences transactions, litigation matters,
patents and regulatory issues on behalf of biopharmaceutical and medical
device companies. For five years in a row, DLA Piper has earned the No.
1 ranking globally for overall deal volume in Mergermarket’s league tables,
and Global Corporate Venturing magazine has named us the 2015 Law
Firm of the Year in Corporate Venture. We have built our reputation by
providing cutting-edge solutions that help innovation thrive.
www.dlapiper.com
Lisa A. Haile, 4365 Executive Drive, Suite 1100, San Diego, CA 92121 | DLA Piper LLP (US) | Attorney Advertising
10996 Torreyana Rd, Suite 200
San Diego, CA 92121-3021
www.Biocom.org
Please send a change of address
or subscription request to Sonali
Vittachi at svittachi@Biocom.org.
U N I V E R S I T Y
O F
C A L I F O R N I A ,
S A N
D I E G O
|
E X T E N S I O N
Achieve your
Life Sciences
educational goals!
Whether you are just entering the Life Sciences field or you are
seeking high-level skill development, UC San Diego Extension has
courses and certificates to fit your continuing education needs.
• Biostatistics
• Biotechnology Project
Management
• Business of Biotech
• Clinical Trials
• Diagnostics
• Drug Discovery/ADMET
• Genomics
• Industrial Biotechnology
(Biofuels, Fermentation)
• Life Sciences IT/Bioinformatics
• Medicinal Chemistry
• Quality Assurance and Control
• Regulatory Affairs
SP13-4012
For your convenience, many of our courses are offered online.
Explore our offerings, today!
(858) 534-9353 | unexbio@ucsd.edu | extension.ucsd.edu/lifesciences